Proj Inf Perspect. 1997 Nov;(23):19.
Burns. 2003 Dec;29(8):793-7
Clin Endocrinol (Oxf). 1993 Apr;38(4):393-8.
Int J Obes Relat Metab Disord 1995 Sep;19(9):614-24
Segal S, Cooper J, Bolognia J., Treatment of lipodermatosclerosis with oxandrolone in a patient with Stanazole-induced hepatotoxicity., J Am Acad Dermatol 2000 Sep;43(3):558-9
Demling RH., Oxandrolone, an anabolic steroid enhances the healing of a cutaneous wound in the rat., Wound Repair Regen 2000 Mar-Apr;8(2):97-102
J Clin Endocrinol Metab. 2004 Oct;89(10):4863-72.
Demling RH, Orgill DP., The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury., J Crit Care 2000 Mar;15(1):12-7
Hart DW, Wolf SE, Ramzy PI, Chinkes DL, Beauford RB, Ferrando AA, Wolfe RR, Herndon DN., Anabolic effects of oxandrolone after severe burn., Ann Surg 2001 Apr;233(4):556-64
Demling RH, DeSanti L., The rate of restoration of body weight after burn injury, using the anabolic agent oxandrolone, is not age dependent., Burns 2001 Feb;27(1):46-51
Demling RH, DeSanti L., Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns., J Trauma 1997 Jul;43(1):47-51
Papadimitriou A, Preece MA, Rolland-Cachera MF, Stanhope R., The anabolic steroid oxandrolone increases muscle mass in prepubertal boys with constitutional delay of growth., J Pediatr Endocrinol Metab 2001 Jun;14(6):725-7
Doeker B, Muller-Michaels J, Andler W, Induction of early puberty in a boy after treatment with oxandrolone? Horm Res 1998;50(1):46-8
J Appl Physiol 96: 1055-1062, 2004. First published October 24, 2003; doi:/ 8750-7587/04
James JS., Wasting syndrome: oral oxandrolone re-released in ., AIDS Treat News 1995 Dec 22;(no 237):3-4
Mt Sinai J Med. 1999 May;66(3):201-5.
Anticoagulants: Patients on anticoagulants such as warfarin should be carefully monitored during anabolic steroid therapy as anabolic steroids may increase sensitivity to oral anticoagulants which may require a concomitant reduction in anticoagulant dosage to achieve a desirable prothrombin time (PT). Anticoagulant patients should be monitored regularly during anabolic steroid therapy, particularly during initiation and termination of therapy. Warfarin patients should have INR and PT monitored throughout androgen therapy and warfarin dosages titrated to achieve the desired INR and PT. Such patients should be monitored for occult bleeding.